Varner, CA
Curtis Varner, Oak Park, CA US
Patent application number | Description | Published |
---|---|---|
20130275877 | USER CONTROLLED DATA SPEED SELECTOR SYSTEMS AND METHODS - A method in accordance with an embodiment allows for a user to change a wireless speed setting for a device. The method includes sending, from a server over a network, information for displaying an interface in a web page to allow a user to change a wireless speed setting for the device. The method further includes receiving, by the server over the network, a selected wireless speed setting as input by the user into the interface. The change of the wireless speed is then performed by sending, to a computer of a wireless network provider, a request to change the wireless speed setting for the device to the selected wireless speed setting. | 10-17-2013 |
20140173111 | DATA USAGE MANAGEMENT SYSTEMS AND METHODS - Systems and methods allow network users to manage their data usage. Various systems and methods are particularly aimed at users of metered data networks that require users to pay based on data usage, and allow for preventing or controlling data usage, so as to assist users in staying within a budget. Some systems and methods provide users with a way to prevent or throttle background data usage that they might not otherwise be aware of, such as background updates by applications that require the downloading of data. Also, some systems and methods allow for the use of compression and/or degradation to reduce data usage, and for the presentation of usage statistics to users to allow users to make more informed data usage decisions. | 06-19-2014 |
Don Varner, Grass Valley, CA US
Patent application number | Description | Published |
---|---|---|
20100071146 | Compound Water-Wiper Apparatus - A water-wiper apparatus has a handle having a height, width, and length with a substantially oval shape in cross-section orthogonal to the length, a major axis of the oval shape in the direction of the height, the handle formed of a rigid or semi-rigid material, a first engagement interface along the length of the handle in a region bisected by the major axis, the engagement interface comprising a channel having a shape and a first width and an opening of a second width less than the first width to the outside of the handle, and a wiper blade of the length of the handle, formed of a flexible material and having a second engagement interface shaped to engage the first engagement interface, engaging the wiper blade with the handle, the wiper blade having a curved side in cross section from the handle to a tip end of a wiper leg away from the handle, the curve of the side having a radius of from one-half inch to one-and-one-half inches. | 03-25-2010 |
Donald Varner, Carmel, CA US
Patent application number | Description | Published |
---|---|---|
20100064459 | SCRUBBING APPARATUS AND METHOD - An apparatus and method that efficiently scrubs and massages a surface without the need for a washcloth and effectively inhibits growth of mold and bacteria. The apparatus is designed to fit within a human hand to facilitate ease in use. The material that the apparatus is made from can be quick drying and antibacterial. The apparatus can be used on both humans and animals for grooming. | 03-18-2010 |
20110113579 | Compound Water-Wiper and Pet Hair/Fur Removal Apparatus and Method - An apparatus and method that efficiently removes water from a surface without the need for a towel and effectively removes hair or fur from a surface. The apparatus is designed to provide a comfort gripping region to a human hand to facilitate ease in use. The material that the apparatus is made from can be static electric attracting to more effectively remove charged particles such as hair or fur from a surface. The apparatus may have various flex edges, including combs, slits and bulges. | 05-19-2011 |
Donald Varner, Hollister, CA US
Patent application number | Description | Published |
---|---|---|
20130008464 | Tool for Removing Ice and Moisture from a Surface - A tool for removing ice and residual moisture from a surface includes a semi-annular attachment having multiple teeth arrayed about the periphery on the forward facing edge thereof, the attachment including a substantially straight-edged scrapper bar disposed laterally across the anterior edge of the attachment opposite the multiple teeth, a semi-annular handle guard affixed to the semi-annular attachment, the handle guard including a laterally disposed handle grip, and a flexible squeegee panel mounted to the semi-annular handle guard along the front peripheral edge thereof, the panel disposed above the multiple tooth array. | 01-10-2013 |
Judith Varner, Encinitas, CA US
Patent application number | Description | Published |
---|---|---|
20100055089 | Methods for Inhibition of Lymphangiogenesis and Tumor Metastasis - The present invention is directed to compositions and methods for inhibiting the development of new lymphatic vessels, and for inhibiting tumor cell dissemination through the lymphatics. In preferred embodiments, the present invention utilizes agents that inhibit the specific binding of integrin alpha4beta1 (α4β1, VLA-4) to one or more of its ligands. The invention further relates to methods for screening test compounds for their ability to inhibit undesirable lymphangiogenesis and/or tumor metastasis. | 03-04-2010 |
Judith A. Varner, Encinitas, CA US
Patent application number | Description | Published |
---|---|---|
20080233108 | METHODS FOR DETECTING AND INHIBITING ANGIOGENESIS USING ANTAGONISTS - The present invention provides methods for reducing or inhibiting angiogenesis in a tissue, by contacting α5β1 integrin in the tissue with an agent that interferes with specific binding of the α5β1 integrin to a ligand expressed in the tissue; and methods of identifying angiogenesis in a tissue, by contacting the tissue with an agent that specifically binds α5β1 integrin, and detecting specific binding of the agent to α5β1 integrin associated with a blood vessel in the tissue. Also provided are methods of diagnosing a pathological condition characterized by angiogenesis in a tissue in an individual. The invention further provides methods of reducing or inhibiting angiogenesis in a tissue in an individual, by administering to the individual an agent that interferes with the specific binding of α5β1 integrin to a ligand expressed in the tissue; and methods of reducing the severity of a pathological condition associated with angiogenesis in an individual, by administering to the individual an agent that interferes with specific binding of α5β1 integrin to a ligand in a tissue associated with the pathological condition. The invention also provides methods of identifying an agent that reduces or inhibits angiogenesis associated with α5β1 integrin expression in a tissue by contacting a tissue exhibiting angiogenesis associated with α5β1 integrin expression with an agent, and detecting a reduction or inhibition of angiogenesis in the tissue. | 09-25-2008 |
20090130124 | Method for altering hematopoietic progenitor cell adhesion, differentiation, and migration - The present invention satisfies the need in the art by providing methods for altering hematopoietic progenitor cell adhesion and/or migration to a target tissue, and for altering hematopoietic progenitor cell differentiation into a second cell type. The invention also provides methods for screening test compounds for altering the level of hematopoietic progenitor cell adhesion and/or migration to a target tissue, and for altering hematopoietic progenitor cell differentiation into a second cell type. The invention further provides methods for isolating hematopoietic progenitor cells. | 05-21-2009 |
20100255502 | Methods for Detecting and Inhibiting Angiogenesis - The present invention provides methods for reducing or inhibiting angiogenesis in a tissue, by contacting α5β1 integrin in the tissue with an agent that interferes with specific binding of the α5β1 integrin to a ligand expressed in the tissue; and methods of identifying angiogenesis in a tissue, by contacting the tissue with an agent that specifically binds α5β1 integrin, and detecting specific binding of the agent to α5β1 integrin associated with a blood vessel in the tissue. Also provided are methods of diagnosing a pathological condition characterized by angiogenesis in a tissue in an individual. The invention further provides methods of reducing or inhibiting angiogenesis in a tissue in an individual, by administering to the individual an agent that interferes with the specific binding of α5β1 integrin to a ligand expressed in the tissue; and methods of reducing the severity of a pathological condition associated with angiogenesis in an individual, by administering to the individual an agent that interferes with specific binding of α5β1 integrin to a ligand in a tissue associated with the pathological condition. The invention also provides methods of identifying an agent that reduces or inhibits angiogenesis associated with α5β1 integrin expression in a tissue by contacting a tissue exhibiting angiogenesis associated with α5β1 integrin expression with an agent, and detecting a reduction or inhibition of angiogenesis in the tissue. | 10-07-2010 |
20100278837 | Compositions And Methods For Reducing Cancer And Inflammation - This invention relates to the discovery of the convergence of diverse receptors and signaling pathways on the PI3gamma dependent activation of VLA4 (integrin a4b1). In particular, the invention relates to the role of myeloid cells in tumor inflammation and metastasis. The invention provides methods for inhibiting cancer in a subject comprising administering to a subject having cancer that comprises endothelial cells a therapeutically effective amount of a PI-3-kinase gamma inhibitor that reduces at least one of (a) adhesion of myeloid cells to the endothelial cells, (b) migration of myeloid cells into the cancer, (c) growth of the cancer, (d) activation of integrin a4b1 that is comprised on the myeloid cells, and (e) clustering of integrin a4b1 that is comprised on the myeloid cells. | 11-04-2010 |
20110177528 | METHODS FOR DETECTING AND INHIBITING ANGIOGENESIS - The present invention provides methods for reducing or inhibiting angiogenesis in a tissue, by contacting α5β1 integrin in the tissue with an agent that interferes with specific binding of the α5β1 integrin to a ligand expressed in the tissue; and methods of identifying angiogenesis in a tissue, by contacting the tissue with an agent that specifically binds α5β1 integrin, and detecting specific binding of the agent to α5β1 integrin associated with a blood vessel in the tissue. Also provided are methods of diagnosing a pathological condition characterized by angiogenesis in a tissue in an individual. The invention further provides methods of reducing or inhibiting angiogenesis in a tissue in an individual, by administering to the individual an agent that interferes with the specific binding of α5β1 integrin to a ligand expressed in the tissue; and methods of reducing the severity of a pathological condition associated with angiogenesis in an individual, by administering to the individual an agent that interferes with specific binding of α5β1 integrin to a ligand in a tissue associated with the pathological condition. The invention also provides methods of identifying an agent that reduces or inhibits angiogenesis associated with α5β1 integrin expression in a tissue by contacting a tissue exhibiting angiogenesis associated with α5β1 integrin expression with an agent, and detecting a reduction or inhibition of angiogenesis in the tissue. | 07-21-2011 |
20120128696 | METHODS FOR DETECTING AND INHIBITING ANGIOGENESIS - The present invention provides methods for reducing or inhibiting angiogenesis in a tissue, by contacting α5β1 integrin in the tissue with an agent that interferes with specific binding of the α5β1 integrin to a ligand expressed in the tissue. The invention further provides methods of reducing or inhibiting angiogenesis in a tissue in an individual, by administering to the individual an agent that interferes with the specific binding of α5β1 integrin to a ligand expressed in the tissue; and methods of reducing the severity of a pathological condition associated with angiogenesis in an individual, by administering to the individual an agent that interferes with specific binding of α5β1 integrin to a ligand in a tissue associated with the pathological condition. | 05-24-2012 |
Roseanne Varner, Palo Alto, CA US
Patent application number | Description | Published |
---|---|---|
20130116678 | IMPEDANCE MEDIATED CONTROL OF POWER DELIVERY FOR ELECTROSURGERY - A method of controlling electrosurgical power delivery is based on a comparison of sensed tissue impedance to various impedance threshold values. Energy is delivered to tissue in a sealing cycle as a series of pulses. A pulse has a profile with a preset energy starting value that increases at a ramping rate to a preset end value. Sensed impedance data are monitored throughout each pulse and compared to each of an impedance threshold value for RF setpoint, an impedance threshold value for cumulative time, and an impedance threshold value for energy cutback. Based on sensed impedance during a pulse, the profile of a subsequent pulse can be modified. In the event of a high impedance event that reflects low tissue presence, energy may be cutback. A sealing cycle is stopped when a cumulative amount of time with an impedance value over the impedance cumulative time threshold value reaches a limit. | 05-09-2013 |
Signe E. Varner, Los Angeles, CA US
Patent application number | Description | Published |
---|---|---|
20110159073 | METHODS AND DEVICES FOR THE TREATMENT OF OCULAR CONDITIONS - Featured is a method for instilling one or more bioactive agents into ocular tissue within an eye of a patient for the treatment of an ocular condition, the method comprising concurrently using at least two of the following bioactive agent delivery methods (A)-(C): (A) implanting a sustained release delivery device comprising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more bioactive agents subretinally; and (C) instilling (e.g., injecting or delivering by ocular iontophoresis) one or more bioactive agents into the vitreous humor of the eye. | 06-30-2011 |
Signe Erickson Varner, Menlo Park, CA US
Patent application number | Description | Published |
---|---|---|
20130304031 | Reservoir Device for Intraocular Drug Delivery - A delivery device that allows for the sustained release of an agent, particularly useful for the sustained release of a therapeutic agent to limited access regions, such as the posterior chamber of the eye and inner ear. The delivery device is minimally invasive, refillable and may be easily fixed to the treatment area. The delivery device includes a hollow body with an inlet port at its proximal end for insertion of the agent, a reservoir for holding the agent and a delivery mechanism for the sustained delivery of the agent from the reservoir to the patient. | 11-14-2013 |
20140243795 | Reservoir Device for Intraocular Drug Delivery - A delivery device that allows for the sustained release of an agent, particularly useful for the sustained release of a therapeutic agent to limited access regions, such as the posterior chamber of the eye and inner ear. The delivery device is minimally invasive, refillable and may be easily fixed to the treatment area. The delivery device includes a hollow body with an inlet port at its proximal end for insertion of the agent, a reservoir for holding the agent and a delivery mechanism for the sustained delivery of the agent from the reservoir to the patient. | 08-28-2014 |
Signe Erickson Varner, Los Angeles, CA US
Patent application number | Description | Published |
---|---|---|
20110098686 | Reservoir Device for Intraocular Drug Delivery - A delivery device that allows for the sustained release of an agent, particularly useful for the sustained release of a therapeutic agent to limited access regions, such as the posterior chamber of the eye and inner ear. The delivery device is minimally invasive, refillable and may be easily fixed to the treatment area. The delivery device includes a hollow body with an inlet port at its proximal end for insertion of the agent, a reservoir for holding the agent and a delivery mechanism for the sustained delivery of the agent from the reservoir to the patient. | 04-28-2011 |